Novel peptide compound or pharmaceutically acceptable salt thereof
By developing a new peptide compound composed of 9 amino acid residues, the existing anti-inflammatory drugs have been solved, with high toxicity, serious side effects and high production costs, and safe and efficient anti-inflammatory effects have been achieved.
Patent Information
- Application Number
- CN202080037370.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-21
- Filing Date
- 2020-05-20
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-05-20
AI Technical Summary
Existing anti-inflammatory drugs have problems such as high toxicity, serious side effects and high production costs, and it is difficult to selectively act on substances that cause inflammation, resulting in limited therapeutic effects and low production efficiency.
A novel peptide compound is developed, consisting of 9 amino acid residues, linked by specific peptide bonds, has excellent anti-inflammatory activity, and is not cytotoxic and can be economically produced in large quantities.
It achieves safe and efficient anti-inflammatory effects, avoids the toxicity and side effects of traditional anti-inflammatory drugs, and has low production costs, making it suitable for long-term use.
Smart Images

Figure CN114269769B_ABST
Abstract
Description
Technical Field
[0001] Various embodiments of the present invention relate to novel peptide compounds or pharmaceutically acceptable salts thereof. Specifically, various embodiments of the present invention relate to novel peptide compounds or pharmaceutically acceptable salts thereof having anti-inflammatory activity. Background Art
[0002] Recently, with economic development, the proportion of elderly people has been increasing due to the development of medical technology and the extension of average life expectancy, and chronic inflammatory diseases such as atopy and asthma are on the rise due to abnormal immune system leading to chronic inflammatory reactions due to environmental pollution and increased stress.
[0003] In general, inflammatory response is a defense mechanism of biological tissues against external stimuli such as bacterial infection or internal stimuli such as metabolites in the body. It is caused by the production of cytokines such as TNFα, IL-1β, IL-6 and nitric oxide (NO), which are various inflammatory regulators in cells. In addition, lipopolysaccharide (LPS), also known as endotoxin, exists in the outer membrane of Gram-negative bacteria and can induce the activation of intracellular transcription factor NF-κB (nuclear facter-κB) in macrophages or monocytes, thereby causing the gene expression of inflammatory cytokines, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and producing inflammatory mediators.
[0004] Therefore, for the regulation of inflammatory response, the expression of iNOS, COX-2 or NF-κB and the regulation of the secretion of cytokines and nitric oxide are key factors, and substances that regulate the activity of these factors have attracted attention as preventive and therapeutic agents for inflammatory diseases.
[0005] At present, the substances used for anti-inflammatory purposes include non-steroidal such as flufenamic acid, ibuprofen, benzydamine, indomethacin, etc.; steroids such as prednisolone, dexamethasone, hydrocortisone and betamethasone, etc., but these substances are highly toxic and have many serious side effects, such as liver damage, cancer and stroke, which limit their use. In addition, since they cannot selectively act on substances that cause inflammation, the problem of inducing severe immunosuppression sometimes occurs. Therefore, anti-inflammatory agents using natural products that are safe for the body and have the advantage of being easy to take for a long time compared to conventional drugs are being developed. In the case of anti-inflammatory substances extracted from natural products, the effective concentration showing efficacy is weak, and since they must be cultivated in farmland, etc., there are problems such as high production costs.
[0006] In order to improve the above problems, a new concept of anti-inflammatory agents is being developed as a substitute for existing chemical anti-inflammatory agents or anti-inflammatory agents using natural products, and in particular, a large number of studies are being conducted to synthesize peptides having anti-inflammatory activity.
[0007] Therefore, the present inventors, while continuing to study substances showing excellent anti-inflammatory activity, developed a peptide that can be economically mass-produced using only 9 amino acid residues, and confirmed that the peptide has no cytotoxicity and has excellent anti-inflammatory activity, thereby completing the present invention. Summary of the invention
[0008] Technical issues
[0009] Various embodiments of the present invention provide novel peptide compounds or pharmaceutically acceptable salts thereof.
[0010] Means of solving the problem
[0011] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 1.
[0012] Chemical formula 1: A1-A2-A3-A4-A5,
[0013] In the above chemical formula 1, A1 to A5 are connected by a peptide bond as shown in the following chemical formula 2, A1 is substituted or unsubstituted proline or glutamine,
[0014] A2 is substituted or unsubstituted glycine or aspartic acid,
[0015] A3 is substituted or unsubstituted glutamine or glycine,
[0016] A4 is substituted or unsubstituted aspartic acid or leucine,
[0017] A5 is substituted or unsubstituted glycine or alanine,
[0018] 0 to 2 of A1 to A5 can be independently substituted by one selected from the group consisting of substituted or unsubstituted glycine, alanine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine and arginine,
[0019] Chemical formula 2:
[0020]
[0021] wherein B is hydrogen, or is connected to at least one of A1 to A5 for cyclization.
[0022] Effects of the Invention
[0023] The present invention can provide novel peptide compounds of various structures or pharmaceutically acceptable salts thereof that can be used in various fields.
[0024] The novel peptide compound or the pharmaceutically acceptable salt thereof of the present invention has only 5 to 8 amino acid residues and can be economically mass-produced. In addition, it has no cytotoxicity, excellent safety and outstanding anti-inflammatory activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1a , 1b 1c and 1d respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated in Example 10.
[0026] Figure 2a , 2b2c and 2d show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 32, respectively.
[0027] Figure 3a , 3b 3c and 3d respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 41.
[0028] Figure 4a , 4b 4C and 4D respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 55.
[0029] Figure 5a 5b and 5c respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 59.
[0030] Figure 6a , 6b and 6c respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 91.
[0031] Figure 7a 7b and 7c respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 30.
[0032] Figure 8a 8b and 8c respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 11.
[0033] Figure 9a 9b and 9c respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 86.
[0034] Fig.10a , 10b and 10c respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα in LPS-stimulated macrophages treated with Example 103.
[0035] Fig.11a , 11b and 11c respectively show the results of measuring the expression levels of IL-1β, IL-6 and TNFα treated in Example 104 in LPS-stimulated macrophages. DETAILED DESCRIPTION
[0036] Hereinafter, various embodiments of the present specification are described with reference to the accompanying drawings. The embodiments and the terms used therein are not intended to limit the technology described in this document to a specific implementation, but should be understood to include various changes, equivalents and / or substitutes of the embodiments.
[0037] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 1.
[0038] Chemical formula 1: A1-A2-A3-A4-A5,
[0039] In the above chemical formula 1, A1 to A5 are connected by a peptide bond as shown in the following chemical formula 2:
[0040] A1 is substituted or unsubstituted proline or glutamine,
[0041] A2 is substituted or unsubstituted glycine or aspartic acid,
[0042] A3 is substituted or unsubstituted glutamine or glycine,
[0043] A4 is substituted or unsubstituted aspartic acid or leucine,
[0044] A5 is substituted or unsubstituted glycine or alanine,
[0045] 0 to 2 of A1 to A5 can be independently substituted by one selected from the group consisting of substituted or unsubstituted glycine, alanine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine and arginine,
[0046] Chemical formula 2:
[0047]
[0048] wherein B is hydrogen, or is connected to at least one of A1 to A5 for cyclization.
[0049] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 3.
[0050] Chemical formula 3: A1-A2-A3-A4-A5-A6,
[0051] In the above chemical formula 3, A1 to A6 are connected by a peptide bond as shown in the following chemical formula 2:
[0052] A1 is substituted or unsubstituted proline or glutamine,
[0053] A2 is substituted or unsubstituted glycine or aspartic acid,
[0054] A3 is substituted or unsubstituted glutamine or glycine,
[0055] A4 is substituted or unsubstituted aspartic acid or leucine,
[0056] A5 is substituted or unsubstituted glycine or alanine,
[0057] A6 is substituted or unsubstituted leucine or glycine,
[0058] 0 to 2 of A1 to A6 can be independently substituted by one selected from the group consisting of substituted or unsubstituted glycine, alanine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine and arginine,
[0059] Chemical formula 2:
[0060]
[0061] wherein B is hydrogen, or is connected to at least one of A1 to A6 for cyclization.
[0062] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 4.
[0063] Chemical formula 4: A1-A2-A3-A4-A5-A6-A7,
[0064] In the above chemical formula 4, A1 to A7 are connected by a peptide bond as shown in the following chemical formula 2:
[0065] A1 is substituted or unsubstituted proline or glutamine,
[0066] A2 is substituted or unsubstituted glycine or aspartic acid,
[0067] A3 is substituted or unsubstituted glutamine or glycine,
[0068] A4 is substituted or unsubstituted aspartic acid or leucine,
[0069] A5 is substituted or unsubstituted glycine or alanine,
[0070] A6 is substituted or unsubstituted leucine or glycine,
[0071] A7 is substituted or unsubstituted alanine or proline,
[0072] 0 to 3 of A1 to A7 can be independently substituted by one selected from the group consisting of substituted or unsubstituted glycine, alanine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine and arginine,
[0073] Chemical formula 2:
[0074]
[0075] wherein B is hydrogen, or is connected to at least one of A1 to A7 for cyclization.
[0076] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 5.
[0077] Chemical formula 5: A1-A2-A3-A4-A5-A6-A7-A8,
[0078] In the above chemical formula 5, A1 to A8 are connected by a peptide bond as shown in the following chemical formula 2:
[0079] A1 is substituted or unsubstituted proline or glutamine,
[0080] A2 is substituted or unsubstituted glycine or aspartic acid,
[0081] A3 is substituted or unsubstituted glutamine or glycine,
[0082] A4 is substituted or unsubstituted aspartic acid or leucine,
[0083] A5 is substituted or unsubstituted glycine or alanine,
[0084] A6 is substituted or unsubstituted leucine or glycine,
[0085] A7 is substituted or unsubstituted alanine or proline,
[0086] A8 is substituted or unsubstituted glycine or lysine,
[0087] 0 to 3 of A1 to A8 can be independently substituted by one selected from the group consisting of substituted or unsubstituted glycine, alanine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine and arginine,
[0088] Chemical formula 2:
[0089]
[0090] wherein B is hydrogen, or is connected to at least one of A1 to A8 for cyclization.
[0091] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 6.
[0092] Chemical formula 6:
[0093]
[0094] Among them, R 1 and R 2 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, -X2, -Rb, -O-, =O, -CH 2 Orb or -ORb, X2 is halogen, Rb is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 an aralkyl group or a substituted or unsubstituted heterocyclic group,
[0095] R 3 To R 7 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-10 Alkoxy, substituted or unsubstituted C 1-10 Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12 Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0096] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C 1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group,
[0097] B is hydrogen or 5 To R 6 At least one of the two is connected to carry out circularization.
[0098] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 7.
[0099] Chemical formula 7:
[0100]
[0101] Among them, R 1 and R 2 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, -X2, -Rb, -O-, =O, -CH 2 Orb or -ORb, X2 is halogen, Rb is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 an aralkyl group or a substituted or unsubstituted heterocyclic group,
[0102] R 3 To R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C1-10 Alkoxy, substituted or unsubstituted C 1-10 Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12 Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0103] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C 1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group,
[0104] B is hydrogen or 5 To R 6 and at least one of R' is linked to undergo cyclization,
[0105] R' is represented by any one of the following Chemical Formulas 8 to 10.
[0106] Chemical formula 8:
[0107]
[0108] Chemical formula 9:
[0109]
[0110] Chemical formula 10:
[0111]
[0112] Among them, R 8 To R 11 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-10 Alkoxy, substituted or unsubstituted C 1-10 Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12 Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0113] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C 1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group.
[0114] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 11.
[0115] Chemical formula 11:
[0116]
[0117] Among them, R 1 and R 2 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, -X2, -Rb, -O-, =O, -CH 2 Orb or -ORb, X2 is halogen, Rb is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 an aralkyl group or a substituted or unsubstituted heterocyclic group,
[0118] R 3 , R 4 , R 6 and R 7 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-10 Alkoxy, substituted or unsubstituted C 1-10Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12 Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0119] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C 1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group.
[0120] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in Chemical Formula 12 below.
[0121] Chemical formula 12:
[0122]
[0123] Among them, R 1 and R 2 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, -X2, -Rb, -O-, =O, -CH 2 Orb or -ORb, X2 is halogen, Rb is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 an aralkyl group or a substituted or unsubstituted heterocyclic group,
[0124] R 3 , R 4 and R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-10 Alkoxy, substituted or unsubstituted C 1-10 Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12 Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0125] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C 1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group,
[0126] R' is represented by any one of the following Chemical Formulas 13 to 15.
[0127] Chemical formula 13:
[0128]
[0129] Chemical formula 14:
[0130]
[0131] Chemical formula 15:
[0132]
[0133] Among them, R 8 To R 11 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-10 Alkoxy, substituted or unsubstituted C 1-10 Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12 Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0134] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C 1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group.
[0135] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention has a continuous or discontinuous 5mer to 8mer configuration in the amino acid sequence of Hyp-Gly-Gln-Asp-Gly-Leu-Ala-Gly-Pro-Lys.
[0136] The above 5mer to 8mer are linear or at least partially cyclized.
[0137] On the other hand, the at least partially cyclized peptide may be a peptide comprising Asu, wherein Asu is aspartimide or aminosuccinimide.
[0138] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention has a continuous or discontinuous 5mer to 8mer configuration in the amino acid sequence of Hyp-Gly-Gln-Asp-Gly-Leu-Ala-Gly-Pro-Lys.
[0139] The above 5mer to 8mer are linear or at least partially cyclized,
[0140] In the above 5mer to 8mer configurations, at least one amino acid has a substituted configuration selected from the group consisting of substituted or unsubstituted glycine, alanine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine and arginine.
[0141] In another aspect, the at least partially cyclized peptide may be a peptide comprising Asu, wherein Asu is asparagine or aminosuccinimide.
[0142] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in Chemical Formula 16 below.
[0143] Chemical formula 16:
[0144]
[0145] R 3 , R 4 , R 6 and R 7 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-10 Alkoxy, substituted or unsubstituted C 1-10 Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0146] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C 1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group,
[0147] B is hydrogen, or aspartic acid and R 6 At least one of the two is connected to carry out circularization.
[0148] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in Chemical Formula 17 below.
[0149] Chemical formula 17:
[0150]
[0151] R 3 , R 4 and R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-10 Alkoxy, substituted or unsubstituted C 1-10 Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12 Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0152] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C 1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group,
[0153] B is hydrogen, or aspartic acid and R 6 At least one of them is connected to carry out cyclization,
[0154] R' is represented by any one of the following Chemical Formulas 8 to 10.
[0155] Chemical formula 8:
[0156]
[0157] Chemical formula 9:
[0158]
[0159] Chemical formula 10:
[0160]
[0161] Among them, R 8 To R 11 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-10 Alkoxy, substituted or unsubstituted C 1-10 Haloalkyl, substituted or unsubstituted C 2-10 Alkenyl, substituted or unsubstituted C 2-10 Alkynyl, substituted or unsubstituted C 1-10 Alkylene, substituted or unsubstituted C 1-10 Alkenylene, substituted or unsubstituted C 1-10 Alkyne, substituted or unsubstituted C 5-12 Aryl, substituted or unsubstituted C 7-12 Arylalkyl, substituted or unsubstituted C 5-14 Aromatic, substituted or unsubstituted C 8-16 Aralkenyl, substituted or unsubstituted C 3-10 Heteroalkyl, substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 3-10 Heterocycloalkyl or substituted or unsubstituted C 5-12 Heteroaryl, the above heteroalkyl, heterocycloalkyl or heteroaryl includes at least one N, O or S,
[0162] The above substitutions are substituted by non-hydrogen substituents, and the non-hydrogen substituents can be selected from -Rx, -Ra, -O-, =O, -ORa, -SRa, -S-, -N(Ra)2, -N+(Ra)3, =NRa, -C(Rx)3, -CN, -OCN, -SCN, -N=C=O, -NSC, -NO, -NO2, =N-OH, =N2, -N3, -NHC(=O)Ra, -C(=O)Ra, -C(=O)NRaRa, -S(=O)2O-, -S(=O)2OH, -S(=O)2Ra, -OS(=O)2ORa, -S(=O)2N at least one of the group consisting of Ra, -S(=O)Ra, -OP(=O)(ORa)2, -C(=O)Ra, alkylene-C(=O)Ra, -C(=S)Ra, -C(=O)ORa, alkylene-C(=O)ORa, -C(=O)O-, alkylene-C(=O)O-, -C(=S)ORa, -C(=O)SRa, -C(=S)SRa, -C(=O)NRaRa, alkylene-C(=O)NRaRa, -C(=S)NRaRa and -C(-NRa)NRaNRa, Rx is F, Cl, Br or I, Ra is H, C1-6 Alkyl, C 5-12 Aryl, C 7-12 Aralkyl or heterocyclic group.
[0163] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in Chemical Formula 17 below.
[0164] Chemical formula 17: X 1 -X 2 -X 3 -X 4 -X 5 ,
[0165] In the above chemical formula 17,
[0166] X 1 For selected from Hyp, D Hyp, cis-4F-Pro, trans-4NH 2 -Pro, 4,4-difluoro-Pro, 4-methylene-Pro, 4,4-dimethyl-Pro and Pro,
[0167] X 2 is one selected from the group consisting of Gly, Ala, Val and Leu,
[0168] X 3 is Gln or D Gln,
[0169] X 4 is one selected from the group consisting of Asp, Ala, Asp substituted with isopropyl ester, D Asp, Glu, Leu and Asu,
[0170] X 5 It is one selected from the group consisting of Val, Leu, Ala, Gly, Aib and Gly substituted with isopropyl ester.
[0171] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in Chemical Formula 18 below.
[0172] Chemical formula 18: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 ,
[0173] In the above chemical formula 18,
[0174] X 1 For selected from Hyp, D Hyp, cis-4F-Pro, trans-4NH 2-Pro, 4,4-difluoro-Pro, 4-methylene-Pro, 4,4-dimethyl-Pro and Pro,
[0175] X 2 is one selected from the group consisting of Gly, Ala, Val and Leu,
[0176] X 3 is Gln or D Gln,
[0177] X 4 is one selected from the group consisting of Asp, Ala, Asp substituted with isopropyl ester, D Asp, Glu, Leu, Asu, Asn, His and Aib,
[0178] X 5 is one selected from the group consisting of Val, Leu, Ala, Gly, Aib and Gly substituted with isopropyl ester,
[0179] X 6 is one selected from the group consisting of Leu, D Leu, Leu substituted with isopropyl ester, and Val.
[0180] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in Chemical Formula 19 below.
[0181] Chemical formula 19: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 ,
[0182] In the above chemical formula 19,
[0183] X 1 For selected from Hyp, D Hyp, cis-4F-Pro, trans-4NH 2 -Pro, 4,4-difluoro-Pro, 4-methylene-Pro, 4,4-dimethyl-Pro and Pro,
[0184] X 2 is one selected from the group consisting of Gly, Ala, Val and Leu,
[0185] X 3 is Gln or D Gln,
[0186] X 4is one selected from the group consisting of Asp, Ala, Asp substituted with isopropyl ester, D Asp, Glu, Leu, Asu, Asn, His and Aib,
[0187] X 5 is one selected from the group consisting of Val, Leu, Ala, Gly, Aib, Gly substituted with isopropyl ester, tert Leu, Phenyl Gly,
[0188] X 6 is one selected from the group consisting of Leu, D Leu, Leu substituted with isopropyl ester, and Val,
[0189] X 7 It is one selected from the group consisting of Ala, D Ala and Ala substituted with isopropyl ester.
[0190] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 20.
[0191] Chemical formula 20: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 ,
[0192] In the above chemical formula 20,
[0193] X 1 For selected from Hyp, D Hyp, cis-4F-Pro, trans-4NH 2 -Pro, 4,4-difluoro-Pro, 4-methylene-Pro, 4,4-dimethyl-Pro and Pro,
[0194] X 2 is one selected from the group consisting of Gly, Ala, Val and Leu,
[0195] X 3 is Gln or D Gln,
[0196] X 4 is one selected from the group consisting of Asp, Ala, Asp substituted with isopropyl ester, D Asp, Glu, Leu and Asu,
[0197] X 5 is one selected from the group consisting of Val, Leu, Ala, Gly, Aib and Gly substituted with isopropyl ester,
[0198] X 6 is one selected from the group consisting of Leu, D Leu, Leu substituted with isopropyl ester, and Val,
[0199] X 7 is one selected from the group consisting of Ala, D Ala and Ala substituted with isopropyl ester,
[0200] X 8 For Gly.
[0201] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in the following Chemical Formula 21.
[0202] Chemical formula 21: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 ,
[0203] In the above chemical formula 21,
[0204] X 1 is Gln or Gly,
[0205] X 2 is one selected from the group consisting of Leu, Gln, Asp, Glu and Asu,
[0206] X 3 is one selected from the group consisting of Gly, Asp and Ala,
[0207] X 4 is Leu or Gly,
[0208] X 5 is one selected from the group consisting of Ala, Leu and Pro,
[0209] X 6 It is one selected from the group consisting of Gly, Ala and Lys.
[0210] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in Chemical Formula 22 below.
[0211] Chemical formula 22: X 1 -Gly-X 3 -X 4 -Gly-Pro-Lys,
[0212] In the above chemical formula 22,
[0213] X1 is one selected from the group consisting of Asp, Leu, Hyp and Asu,
[0214] X 3 is Leu or Gln,
[0215] X 4 It is Ala or Asp.
[0216] The novel peptide compound or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is shown in Chemical Formula 23 below.
[0217] Chemical formula 23: Gln-X 2 -Gly-Leu-Ala-Gly-Pro-Lys,
[0218] In the above chemical formula 23,
[0219] X 2 It is at least one of Asp, Leu and Asu.
[0220] In the above chemical formulas 17 to 23, Hyp is (2S, 4R) Trans-4-hydroxy-L-proline, Gly is glycine, Gln is glutamine, Asp is aspartic acid, Leu is leucine, Ala is alanine, Pro is proline, Val is valine, Tert-Leu is L-α-tert-butylglycine, Asu is asparagine or aminosuccinimide, Lys is lysine, isopropyl ester is a derivative in which the terminal group of the amino acid is substituted with isopropyl ester, Aib is 2-aminoisobutyric acid, cis-4F-Pro is Cis-4-fluoro-L-proline, trans-4NH 2 -Pro is trans-4-amino-L-proline, 4,4-difluoro-Pro is 4-difluoro-L-proline, 4-methylene-Pro is 4-methylene-L-proline, 4,4-dimethyl Pro is 4,4-dimethyl-L-proline, D Hyp is trans-4-hydroxy-D-proline, D Gln is D-glutamine, D Asp is D-aspartic acid, D Leu is D-leucine, Asn is asparagine, and His is histidine.
[0221] The novel peptide compound of the present invention or a pharmaceutically acceptable salt thereof has only 5 to 8 amino acid residues and can be economically produced in large quantities.
[0222] The novel peptide compound or its pharmaceutically acceptable salt as described above is non-cytotoxic, has excellent safety and anti-inflammatory activity. The term "anti-inflammatory" used in the present invention means preventing, treating or improving inflammation. Among them, the above-mentioned inflammation refers to diseases induced by infections, wounds, surgeries, burns, frostbite, electrical stimulation and chemicals caused by exogenous infectious agents (bacteria, fungi, viruses, various allergens, etc.), and the above-mentioned diseases include dermatitis, inflammatory bowel disease, gastric ulcer, colitis, cystitis, rhinitis, tonsillitis, asthma, etc., but are not particularly limited thereto.
[0223] The present invention provides a pharmaceutical composition for preventing or treating inflammation, comprising the novel peptide compound or a pharmaceutically acceptable salt thereof as an effective ingredient.
[0224] The pharmaceutical composition for preventing or treating inflammation of the present invention may contain the novel peptide compound or a pharmaceutically acceptable salt thereof at a concentration of 0.001 μM to 10 μM. The anti-inflammatory effect of the composition containing the peptide with anti-inflammatory activity at a concentration of less than 0.001 μM is weak, and when the concentration exceeds 10 μM, the effect increases disproportionately with the increase in concentration and the efficiency is low, and the stability of the dosage form cannot be ensured.
[0225] The pharmaceutical composition for preventing or treating inflammation of the present invention can be various oral or non-oral dosage forms. In the case of a preparation, a conventional filler, extender, adhesive, wetting agent, disintegrant, surfactant and other diluents or excipients can be used to prepare. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations can be prepared by adding at least one excipient to one or more compounds, such as starch, calcium carbonate, sucrose (sucrose) or lactose (lactose), gelatin, etc. In addition, lubricants such as magnesium stearate, talc, etc. can also be used in addition to excipients.
[0226] Liquid preparations for oral administration may include suspensions, oral liquid preparations, emulsions, syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavors, preservatives, etc. may also be added.
[0227] Preparations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), and injectable esters (such as ethyl oleate), etc. As the base of suppositories, witepsol, polyethylene glycol, tween 61, cocoa butter, laurin, glyceryl gelatin, etc. may be used.
[0228] The administration form of the composition of the present invention can use the form of salt, and can be used alone or in combination with other active compounds and in appropriate groups. For example, the above-mentioned salt can use hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid, etc.
[0229] The composition of the present invention can be administered parenterally or orally as needed, and can be administered once or several times, with the dosage being 0.1 to 500 mg, 1 to 100 mg per kg of body weight per day. The dosage for a specific patient can vary depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of the disease, etc.
[0230] The composition of the present invention can be prepared according to conventional methods into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations such as ointments and creams, suppositories and sterile injections, etc. for use.
[0231] The composition of the present invention can be administered to mammals such as rats, mice, livestock and humans by various routes such as non-oral and oral administration, and all modes of administration such as oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection can be contemplated.
[0232] On the other hand, the composition of the present invention has no serious toxicity and side effects, and therefore can be used with confidence even if used for a long period of time for preventive purposes.
[0233] The present invention provides a food composition for preventing or improving inflammation, comprising the novel peptide compound or a pharmaceutically acceptable salt thereof as an effective ingredient.
[0234] The food composition for preventing or improving inflammation of the present invention may contain a novel peptide compound or a pharmaceutically acceptable salt thereof at a concentration of 0.001 μM to 10 μM. The anti-inflammatory effect of a composition containing a peptide with anti-inflammatory activity at a concentration of less than 0.001 μM is weak, and when the concentration exceeds 10 μM, the effect increases disproportionately with the increase in concentration and is inefficient, and the stability of the dosage form cannot be ensured.
[0235] The above-mentioned food composition for preventing or improving inflammation is preferably in the form of powder, granules, tablets, capsules or beverages, but is not limited thereto.
[0236] The food of the present invention may be directly added with the novel peptide compound of the present invention or a pharmaceutically acceptable salt thereof, or used together with other foods or food ingredients, and may be appropriately used according to conventional methods.
[0237] The types of the above-mentioned food are not limited. Examples of foods to which the novel peptide compound of the present invention or a pharmaceutically acceptable salt thereof can be added include meat, sausages, bread, chocolate, candies, snacks, biscuits, pizza, ramen, other noodles, chewing gum, dairy products such as ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and multivitamins, including all foods in the conventional sense.
[0238] The beverage composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, such as conventional beverages. The natural carbohydrates mentioned above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As sweeteners, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame can be used.
[0239] In addition to the above, food of the present invention can also contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectin acid and its salt, alginic acid and its salt, organic acid, protective colloid thickener, pH regulator, stabilizer, preservative, glycerine, alcohol, the carbonating agent used in carbonated beverage etc. In addition, it can also contain the pulp used to prepare natural fruit juice, fruit juice beverage and vegetable beverage. These ingredients can be used alone or in combination. The ratio of these additives is not important, but is usually selected to comprise the scope of 0.01 to 0.1 weight portion in every 100 weight portions of the present composition.
[0240] The food composition for preventing or improving inflammation of the present invention can be used as a feed additive or feed.
[0241] When used as a feed additive, the composition can be prepared into a 20 to 90% high concentrate, powder or granule. The feed additive can also contain organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polyphosphate), polyphenols, catechins, α-tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid and other natural antioxidants at least one. When used as a feed, the composition can be prepared in the form of conventional feed and can also contain conventional feed ingredients.
[0242] Feed additives and feeds include: grains, such as ground or crushed wheat, oats, barley, corn and rice; plant protein feeds, such as rapeseed, soybeans and sunflower as main ingredients; animal protein feeds, such as blood meal, meat meal, bone meal, fish meal, and may also include sugars and dairy products, such as dry ingredients made from various milk powders and whey powders, etc. In addition, it may also include nutritional supplements, digestion and absorption enhancers, growth promoters, etc.
[0243] Feed additives can be mixed in edible carriers to give animals alone or with other feed additives. In addition, feed additives can be easily given to animals as topdressing, directly mixing them with animal feed, or administering them in the form of oral preparations separated from feed. When feed additives are administered separately from animal feed, it can be combined with pharmaceutically acceptable edible carriers well known in the art to prepare quick-release or sustained-release preparations. This edible carrier can be solid or liquid, such as corn starch, lactose, sucrose, soybean flakes, peanut oil, olive oil, sesame oil and propylene glycol. When using solid carriers, feed additives can be tablets, capsules, powders, lozenges or sugary tablets, or topdressing in micro-dispersed form. When using liquid carriers, feed additives can be the dosage form of soft gelatin capsules or syrups or suspensions, emulsions or solutions.
[0244] Furthermore, the feed additives and feeds mentioned above may contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, dissolution promoters, etc. The feed additives may be added to animal feeds by dipping, spraying or mixing.
[0245] The feed or feed additive of the present invention can be applied to a variety of animal feeds, including mammals, poultry and fish.
[0246] The above-mentioned mammals include not only pigs, cattle, sheep, goats, laboratory rodents and experimental rodents, but also pets (such as dogs, cats), etc. The above-mentioned poultry include chickens, turkeys, ducks, geese, pheasants and quails, etc., and the above-mentioned fish include trout, etc., but are not limited to these.
[0247] In one specific example, the feed or feed additive can be used to prevent or treat inflammation in pets, including, but not limited to, dogs, cats, mice, rabbits, etc.
[0248] The present invention provides a cosmetic composition comprising the novel peptide compound or a pharmaceutically acceptable salt thereof as an effective ingredient, which has an anti-inflammatory effect.
[0249] The cosmetic composition of the present invention may contain the novel peptide compound or a pharmaceutically acceptable salt thereof at a concentration of 0.001 μM to 10 μM. The anti-inflammatory effect of the composition containing the peptide with anti-inflammatory activity at a concentration of less than 0.001 μM is weak, and when the concentration exceeds 10 μM, the effect increases disproportionately with the increase in concentration and the efficiency is low, and the stability of the dosage form cannot be ensured.
[0250] When the composition of the present invention is used as a cosmetic composition, in addition to the novel peptide compound or a pharmaceutically acceptable salt thereof as an active ingredient, it may also contain ingredients commonly used in cosmetic compositions, for example, conventional adjuvants and carriers, such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances.
[0251] The cosmetic composition can be prepared in any conventional preparation in the art, such as solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleanser, oil, foundation, emulsion foundation, wax foundation and spray, etc., but not limited thereto. More specifically, it can be prepared in the form of nourishing cream, astringent lotion, softening lotion, lotion, essence, nourishing gel or massage cream.
[0252] When the above-mentioned cosmetic composition is in the form of a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicon, bentonite, silicon dioxide, talc or zinc oxide can be used as a carrier component.
[0253] When the above cosmetic composition is in the form of powder or spray, lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate or polyamide powder can be used as a carrier component, especially in the case of spray, a propellant such as chlorofluorocarbon, propane / butane or dimethyl ether is additionally included.
[0254] When the dosage form of the above-mentioned cosmetic composition is a solution or an emulsion, a solvent, a solubilizer or an emulsifier can be used as a carrier component, for example, water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol fatty acid ester, polyethylene glycol or fatty acid ester of sorbitan.
[0255] In the case where the dosage form of the above-mentioned cosmetic composition is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan ester, polyoxyethylene sorbitan ester; crystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth gum can be used as a carrier component.
[0256] When the dosage form of the above-mentioned cosmetic composition is a surfactant-containing cleanser, fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazoline derivatives, methyl taurine, sarcosinates, fatty acid amide ether sulfates, alkylamide betaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glyceryl fatty acid esters can be used as carrier components.
[0257] Embodiments of the present invention
[0258] The present invention is described in more detail below by way of examples. These examples are only used to more specifically illustrate the present invention, and the scope of the present invention is not limited to these examples.
[0259] Example: Preparation of peptides
[0260] The peptides of Examples 10 to 125 described in Table 1 below were prepared.
[0261] Table 1
[0262]
[0263]
[0264]
[0265]
[0266] (1) Example 1 (Trityl resin-Lys (Boc) step)
[0267] Add 2.2L of dichloromethane (hereinafter, MC) to 150g of 2-chlorotrityl chloride resin (2-Chlorotrityl resin), stir for 1 hour and then dehydrate. Add 205.22g of Fmoc-Lys(Boc)-OH, 1.8L of MC and 153ml of N,N-diisopropylethylamine (hereinafter, DIEA) to another reactor, stir for 10 minutes to dissolve, add to the reactor containing resin, and stir at room temperature for 4 hours. Stir and dehydrate. Add 1.8L of MC to the dehydrated solid, stir for 10 minutes and then dehydrate, and repeat this process twice. Add 1530ml of MC, 180ml of MeOH, and 90ml of DIEA solution, stir for 30 minutes and then dehydrate, and repeat this process twice. Dry with nitrogen for 15 hours, and then vacuum dry the dried solid at 25°C for 15 hours to obtain 267g of final solid. Calculate the loading rate, the result is 0.82mmol / g.
[0268] (2) Example 2 (Trityl resin-Pro step)
[0269] The loading rate was calculated using the same method as in Example 1 using Fmoc-Pro-OH and the result was 0.61 mmol / g in total.
[0270] (3) Example 3 (Trityl resin-Gly step)
[0271] The loading rate was calculated using the same method as in Example 1 using Fmoc-Gly-OH and the result was 0.96 mmol / g in total.
[0272] (4) Example 4 (Trityl resin-Ala step)
[0273] The loading rate was calculated using the same method as in Example 1 using Fmoc-Ala-OH and the result was 0.87 mmol / g in total.
[0274] (5) Example 5 (Trityl resin-Leu step)
[0275] The loading rate was calculated using the same method as in Example 1 using Fmoc-Leu-OH and the result was 0.97 mmol / g in total.
[0276] (6) Example 6 (Trityl resin-Asp (OtBu) step)
[0277] The loading rate was calculated using the same method as in Example 1 using Fmoc-Asp(OtBu)-OH and the result was 0.94 mmol / g in total.
[0278] (7) Example 7 (Trityl resin-Glu (OtBu) step)
[0279] The loading rate was calculated using the same method as in Example 1 using Fmoc-Glu(OtBu)-OH and the result was 0.62 mmol / g in total.
[0280] (8) Example 8 (Trityl resin-Val step)
[0281] The loading rate was calculated using the same method as in Example 1 using Fmoc-Val-OH and the result was 0.992 mmol / g in total.
[0282] (9) Example 9 (Cleavage Step)
[0283] Add 20% piperidie / DMF (dimethylformamide) 99ml to the compound with the desired amino acid configuration bound to the trityl resin after synthesis, stir for 10 minutes and then dehydrate. Repeat this process twice. Add DMF 99ml, stir for 10 minutes and then dehydrate. Repeat this process twice. Add MC 99ml, stir for 10 minutes and then dehydrate. Repeat this process three times. Add MC 30ml, TFA (trifluoroacetic acid) 70ml and H 2O 1ml, dissolve and add to the reactor. Stir at room temperature for 4 hours and filter. Concentrate the filtrate under reduced pressure to 1 / 2 of the filtrate volume. Add the concentrate dropwise to the reactor containing 300ml of IPE (Isopropyl Ether) and stir for 30 minutes. Dehydrate the precipitated solid to obtain a crude solid.
[0284] (10) Embodiment 10
[0285] Add 400 ml of 20% piperidine / DMF to 50 mmol of glycine loaded using the same method as in Example 3, stir for 10 minutes and then dehydrate. Repeat this process twice. Add 450 ml of DMF, stir for 10 minutes and then dehydrate. Repeat this process twice. Add 450 ml of MC, stir for 10 minutes and then dehydrate. Repeat this process three times. Add 41.15 g of Fmoc-Asp(OtBu)-OH, 13.52 g of 1-hydroxy-1H-benzotriazole (hereinafter, HOBt), and 900 ml of DMF to another reactor, stir for 10 minutes to dissolve. After adding the solution to the Trityl-Gly reactor, add 31.32 ml of diisopropylcarbodiimide (hereinafter, DIC), stir at room temperature for 4 hours and dehydrate. According to the amino acid configuration in Table 1, a series of processes were repeated and a cleavage step (Example 9) was performed to obtain 16.7 g of a crude solid. 4 g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.8 g of a final solid.
[0286] (11) Embodiment 11
[0287] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.7g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 21.1g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 2.1g of the final solid.
[0288] (12) Embodiment 12
[0289] Add 20% piperidine / DMF 400ml to 50mmol of Alalnine loaded by the same method as in Example 4, stir for 10 minutes and then dehydrate. This process was repeated twice. Add DMF 450ml, stir for 10 minutes and then dehydrate. This process was repeated twice. After adding MC 450ml, stir for 10 minutes and then dehydrate. This process was repeated three times. Add Fmoc-Leu-OH 35.3g, HOBt 13.52g, and DMF 900ml to another reactor, stir for 10 minutes to dissolve. After adding the solution to the Trityl-Ala reactor, add DIC 31.32ml, stir for 4 hours at room temperature and dehydrate. According to the amino acid configuration in Table 1, repeat a series of processes and perform the cleavage step (Example 9) to obtain 24.4g of crude solid. After 4g of crude solid was purified by Prep LC, 2.0g of final solid was obtained by freeze drying.
[0290] (13) Embodiment 13
[0291] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 31.1g of Fmoc-Ala-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 24.4g of crude solid. 4g of crude solid was purified by Prep LC, and 1.6g of final solid was obtained by freeze drying.
[0292] (14) Embodiment 14
[0293] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 31.1g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.2g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.9g of the final solid.
[0294] (15) Example 15
[0295] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Ala-OH 31.13g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 27.5g of crude solid. After 4g of the crude solid was purified by Prep LC, 2.1g of the final solid was obtained by freeze drying.
[0296] (16) Example 16
[0297] 20% piperidine / DMF 400ml was added to 50mmol of Lycine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.73g of Fmoc-Pro-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Lys reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 28.3g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.2g of the final solid.
[0298] (17) Example 17
[0299] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 31.13g of Fmoc-Ala-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 23.1g of crude solid. 4g of the crude solid was purified by Prep LC, and 2.0g of the final solid was obtained by freeze drying.
[0300] (18) Example 18
[0301] 20% piperidine / DMF 400ml was added to 50mmol of Lycine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.73g of Fmoc-Pro-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Lys reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 26.4g of crude solid. 4g of crude solid was purified by Prep LC, and then freeze-dried to obtain 2.9g of final solid.
[0302] (19) Example 19
[0303] 20% piperidine / DMF 400ml was added to 50mmol of Lycine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.73g of Fmoc-Pro-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Lys reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 21.37g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.2g of the final solid.
[0304] (20) Embodiment 20
[0305] 20% piperidine / DMF 400ml was added to 50mmol of Lycine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.73g of Fmoc-Pro-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Lys reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 23.25g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.8g of the final solid.
[0306] (21) Example 21
[0307] 400ml of 20% piperidine / DMF was added to 50mmol of valine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Val reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 23.25g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 1.8g of the final solid.
[0308] (22) Example 22
[0309] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.93g of Fmoc-Val-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.76g of crude solid. 4g of crude solid was purified by Prep LC, and then freeze-dried to obtain 1.4g of final solid.
[0310] (23) Example 23
[0311] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.76g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.8g of the final solid.
[0312] (24) Example 24
[0313] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Ala-OH 35.34g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 30.26g of crude solid. After 4g of the crude solid was purified by Prep LC, 1.9g of the final solid was obtained by freeze drying.
[0314] (25) Example 25
[0315] 20% piperidine / DMF 400ml was added to 50mmol of lysine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Pro-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Lys reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 16.16g of crude solid. 4g of crude solid was purified by Prep LC, and 2.7g of final solid was obtained by freeze drying.
[0316] (26) Example 26
[0317] 20% piperidine / DMF 400ml was added to 50mmol of lysine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.73g of Fmoc-Pro-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Lys reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.63g of crude solid. 4g of the crude solid was purified by Prep LC, and 3.0g of the final solid was obtained by freeze drying.
[0318] (27) Example 27
[0319] 20% piperidine / DMF 400ml was added to 50mmol of lysine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.73g of Fmoc-Pro-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Lys reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.63g of crude solid. 4g of the crude solid was purified by Prep LC, and 3.0g of the final solid was obtained by freeze drying.
[0320] (28) Example 28
[0321] 20% piperidine / DMF 400ml was added to 50mmol of lysine loaded by the same method as in Example 1, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.73g of Fmoc-Pro-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Lys reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 21.35g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.7g of the final solid.
[0322] (29) Example 29
[0323] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.80g of crude solid. 4g of crude solid was purified by Prep LC, and 3.3g of final solid was obtained by freeze drying.
[0324] (30) Embodiment 30
[0325] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Ala-OH 31.13g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 19.28g of crude solid. After 4g of the crude solid was purified by Prep LC, 1.9g of the final solid was obtained by freeze drying.
[0326] (31) Example 31
[0327] 20% piperidine / DMF 400ml was added to 50mmol of proline loaded by the same method as in Example 2, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. MC 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Gly-OH 29.73g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Pro reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.87g of crude solid. After 4g of the crude solid was purified by Prep LC, 2.4g of the final solid was obtained by freeze drying.
[0328] (32) Example 32
[0329] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Asp(OtBu)-OH 41.14g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.30g of crude solid. After 4g of the crude solid was purified by PrepLC, 2.0g of the final solid was obtained by freeze drying.
[0330] (33) Example 33
[0331] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.10g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 2.5g of the final solid.
[0332] (34) Example 34
[0333] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.93g of Fmoc-Val-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.62g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 2.1g of the final solid.
[0334] (35) Example 35
[0335] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 22.48g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.0g of the final solid.
[0336] (36) Example 36
[0337] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Ala-OH 31.13g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 22.12g of crude solid. After 4g of the crude solid was purified by Prep LC, 2.1g of the final solid was obtained by freeze drying.
[0338] (37) Example 37
[0339] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 22.32g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.9g of the final solid.
[0340] (38) Example 38
[0341] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 24.80g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.1g of the final solid.
[0342] (39) Example 39
[0343] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 24.50g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.7g of the final solid.
[0344] (40) Embodiment 40
[0345] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 15.26g of crude solid. 4g of crude solid was purified by PrepLC, and 2.4g of final solid was obtained by freeze drying.
[0346] (41) Example 41
[0347] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 15.91g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 1.5g of the final solid.
[0348] (42) Example 42
[0349] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 19.82g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 1.6g of the final solid.
[0350] (43) Example 43
[0351] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.90g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 0.9g of the final solid.
[0352] (44) Example 44
[0353] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Asp(OtBu)-OH 41.14g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 14.32g of crude solid. After 4g of the crude solid was purified by PrepLC, 1.7g of the final solid was obtained by freeze drying.
[0354] (45) Example 45
[0355] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.62g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.2g of the final solid.
[0356] (46) Example 46
[0357] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Gly-OH 29.73g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.00g of crude solid. After 4g of the crude solid was purified by Prep LC, 1.5g of the final solid was obtained by freeze drying.
[0358] (47) Example 47
[0359] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.81g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.2g of the final solid.
[0360] (48) Example 48
[0361] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.81g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.2g of the final solid.
[0362] (49) Example 49
[0363] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 21.54g of crude solid. 4g of crude solid was purified by Prep LC, and then freeze-dried to obtain 2.4g of final solid.
[0364] (50) Embodiment 50
[0365] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.23g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.6g of the final solid.
[0366] (51) Example 51
[0367] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 9.14g of crude solid. 4g of crude solid was purified by Prep LC, and then freeze-dried to obtain 1.5g of final solid.
[0368] (52) Example 52
[0369] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Leu-OH 35.34g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.23g of crude solid. After 4g of the crude solid was purified by Prep LC, 1.5g of the final solid was obtained by freeze drying.
[0370] (53) Example 53
[0371] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 10.56g of crude solid. 4g of the crude solid was purified by Prep LC, and 0.9g of the final solid was obtained by freeze drying.
[0372] (54) Example 54
[0373] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 13.94g of crude solid. 4g of crude solid was purified by Prep LC, and then freeze-dried to obtain 1.2g of final solid.
[0374] (55) Example 55
[0375] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.15g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.29g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 1.8g of the final solid.
[0376] (56) Example 56
[0377] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.69g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.1g of the final solid.
[0378] (57) Example 57
[0379] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 21.09g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.1g of the final solid.
[0380] (58) Example 58
[0381] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.15g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 15.67g of crude solid. 4g of crude solid was purified by PrepLC and freeze-dried to obtain 1.3g of final solid.
[0382] (59) Example 59
[0383] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.15g of Fmoc-D Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.21g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 2.2g of the final solid.
[0384] (60) Embodiment 60
[0385] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.48g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.9g of the final solid.
[0386] (61) Example 61
[0387] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 21.32g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.6g of the final solid.
[0388] (62) Example 62
[0389] 20% piperidine / DMF 400ml was added to 50mmol of D-leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-D Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 24.76g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.9g of the final solid.
[0390] (63) Example 63
[0391] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 23.68g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.6g of the final solid.
[0392] (64) Example 64
[0393] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 24.15g of crude solid. 4g of crude solid was purified by Prep LC, and 1.7g of final solid was obtained by freeze drying.
[0394] (65) Example 65
[0395] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-D Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 26.98g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.7g of the final solid.
[0396] (66) Example 66
[0397] 20% piperidine / DMF 400ml was added to 50mmol of D-alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-D Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 22.78g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.9g of the final solid.
[0398] (67) Example 67
[0399] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 42.54g of Fmoc-Glu(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.18g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 1.6g of the final solid.
[0400] (68) Example 68
[0401] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Gly-OH 29.73g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 19.11g of crude solid. After 4g of the crude solid was purified by Prep LC, 2.8g of the final solid was obtained by freeze drying.
[0402] (69) Example 69
[0403] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.40g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.2g of the final solid.
[0404] (70) Embodiment 70
[0405] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Ala-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.78g of crude solid. 4g of the crude solid was purified by Prep LC, and 3.1g of the final solid was obtained by freeze drying.
[0406] (71) Example 71
[0407] 20% piperidine / DMF 400ml was added to 50mmol of valine loaded by the same method as in Example 8, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Gly-OH 29.73g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Val reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 15.24g of crude solid. After 4g of the crude solid was purified by Prep LC, 1.1g of the final solid was obtained by freeze drying.
[0408] (72) Example 72
[0409] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.93g of Fmoc-Val-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 22.23g of crude solid. 4g of the crude solid was purified by Prep LC, and 0.8g of the final solid was obtained by freeze drying.
[0410] (73) Example 73
[0411] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.04g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 2.6g of the final solid.
[0412] (74) Example 74
[0413] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Asp(OtBu)-OH 41.14g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.17g of crude solid. After 4g of the crude solid was purified by PrepLC, 2.1g of the final solid was obtained by freeze drying.
[0414] (75) Example 75
[0415] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 16.94g of crude solid. 4g of crude solid was purified by PrepLC, and then freeze-dried to obtain 1.6g of final solid.
[0416] (76) Example 76
[0417] 20% piperidine / DMF 400ml was added to 50mmol of glycine loaded by the same method as in Example 3, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Gly reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 16.87g of crude solid. 4g of the crude solid was purified by PrepLC and freeze-dried to obtain 2.1g of the final solid.
[0418] (77) Example 77
[0419] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. DMF 450ml was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. After adding MC 450ml, the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Gly-OH 29.73g, HOBt 13.52g, and DMF 900ml were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, DIC 31.32ml was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 19.35g of crude solid. After 4g of the crude solid was purified by Prep LC, 1.8g of the final solid was obtained by freeze drying.
[0420] (78) Example 78
[0421] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 19.90g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.2g of the final solid.
[0422] (79) Example 79
[0423] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 14.37g of crude solid. 4g of crude solid was purified by Prep LC, and then freeze-dried to obtain 1.8g of final solid.
[0424] (80) Embodiment 80
[0425] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 21.38g of crude solid. 4g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 2.3g of the final solid.
[0426] (81) Embodiment 81
[0427] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 23.27g of crude solid. 4g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.7g of the final solid.
[0428] (82) Example 82
[0429] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.64g of crude solid. 3g of crude solid was purified by Prep LC, and 1.3g of final solid was obtained by freeze drying.
[0430] (83) Example 83
[0431] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 450ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 14.68g of crude solid. 4g of the crude solid was purified by Prep LC, and 0.5g of the final solid was obtained by freeze drying.
[0432] (84) Example 84
[0433] 20% piperidine / DMF 400ml was added to 50mmol of leucine loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 29.73g of Fmoc-Gly-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 14.68g of crude solid. 3g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.0g of the final solid.
[0434] (85) Embodiment 85
[0435] 20% piperidine / DMF400ml was added to 50mmol of Aib (alpa-Me-Ala) loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.14g of Fmoc-Asp (OtBu) -OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Aib reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 8.96g of crude solid. 1.5g of the crude solid was purified by Prep LC and freeze-dried to obtain 0.3g of the final solid.
[0436] (86) Example 86
[0437] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 15.41g of crude solid. 5g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.42g of the final solid.
[0438] (87) Example 87
[0439] 20% piperidine / DMF 400ml was added to 50mmol of alanine loaded by the same method as in Example 4, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Ala reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 17.53g of crude solid. 3g of crude solid was purified by Prep LC, and 0.53g of final solid was obtained by freeze drying.
[0440] (88) Example 88
[0441] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.76g of crude solid. 5g of the crude solid was purified by Prep LC and freeze-dried to obtain 2.3g of the final solid.
[0442] (89) Embodiment 89
[0443] Add 20% piperidine / DMF 400ml to 50mmol of Leu loaded by the same method as in Example 5, stir for 10 minutes and then dehydrate. This process was repeated twice. Add DMF 450ml, stir for 10 minutes and then dehydrate. This process was repeated twice. Add MC 450ml, stir for 10 minutes and then dehydrate. This process was repeated three times. Add Fmoc-Val-OH 33.93g, HOBt 13.52g, and DMF 900ml to another reactor, stir for 10 minutes to dissolve. After adding the solution to the Trityl-Leu reactor, add DIC 31.32ml, stir at room temperature for 4 hours and dehydrate. According to the amino acid configuration in Table 1, repeat a series of processes and perform the cleavage step (Example 9) to obtain 18.81g of crude solid. After 5g of the crude solid was purified by Prep LC, 1.6g of the final solid was obtained by freeze drying.
[0444] (90) Embodiment 90
[0445] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 42.54g of Fmoc-Glu(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 18.66g of crude solid. 5g of the crude solid was purified by Prep LC and freeze-dried to obtain 2.6g of the final solid.
[0446] (91) Example 91
[0447] 20% piperidine / DMF 400ml was added to 50mmol of Val loaded by the same method as in Example 8, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 42.54g of Fmoc-Glu(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Val reactor, 31.32ml of DIC was added, and the mixture was stirred for 4 hours at room temperature and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 19.74g of crude solid. 5g of the crude solid was purified by Prep LC and freeze-dried to obtain 0.4g of the final solid.
[0448] (92) Example 92
[0449] Add 20% piperidine / DMF 400ml to 50mmol of Ala loaded by the same method as in Example 4, stir for 10 minutes and then dehydrate. This process was repeated twice. Add DMF 450ml, stir for 10 minutes and then dehydrate. This process was repeated twice. Add MC 450ml, stir for 10 minutes and then dehydrate. This process was repeated three times. Add Fmoc-Leu-OH 35.34g, HOBt 13.52g, and DMF 900ml to another reactor, stir for 10 minutes to dissolve. After adding the solution to the Trityl-Ala reactor, add DIC 31.32ml, stir at room temperature for 4 hours and dehydrate. According to the amino acid configuration in Table 1, repeat a series of processes and perform the cleavage step (Example 9) to obtain 22.48g of crude solid. After 3g of the crude solid was purified by Prep LC, 0.11g of the final solid was obtained by freeze drying.
[0450] (93) Example 93
[0451] Add 20% piperidine / DMF 400ml to 50mmol of Ala loaded by the same method as in Example 4, stir for 10 minutes and then dehydrate. This process was repeated twice. Add DMF 450ml, stir for 10 minutes and then dehydrate. This process was repeated twice. Add MC 450ml, stir for 10 minutes and then dehydrate. This process was repeated three times. Add Fmoc-Leu-OH 35.34g, HOBt 13.52g, and DMF 900ml to another reactor, stir for 10 minutes to dissolve. After adding the solution to the Trityl-Ala reactor, add DIC 31.32ml, stir for 4 hours at room temperature and dehydrate. According to the amino acid configuration in Table 1, repeat a series of processes and perform the cleavage step (Example 9) to obtain 20.35g of crude solid. After 3g of the crude solid was purified by Prep LC, 0.65g of the final solid was obtained by freeze drying.
[0452] (94) Example 94
[0453] Add 20% piperidine / DMF 400ml to 50mmol of Ala loaded by the same method as in Example 4, stir for 10 minutes and then dehydrate. This process was repeated twice. Add DMF 450ml, stir for 10 minutes and then dehydrate. This process was repeated twice. Add MC 450ml, stir for 10 minutes and then dehydrate. This process was repeated three times. Add Fmoc-Leu-OH 35.34g, HOBt 13.52g, and DMF 900ml to another reactor, stir for 10 minutes to dissolve. After adding the solution to the Trityl-Ala reactor, add DIC 31.32ml, stir at room temperature for 4 hours and dehydrate. According to the amino acid configuration in Table 1, repeat a series of processes and perform the cleavage step (Example 9) to obtain 23.91g of crude solid. After 3g of the crude solid was purified by Prep LC, 0.67g of the final solid was obtained by freeze drying.
[0454] (95) Example 95
[0455] 20% piperidine / DMF 400ml was added to 50mmol of Val loaded by the same method as in Example 8, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 35.34g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Val reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 15.41g of crude solid. 3g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.17g of the final solid.
[0456] (96) Example 96
[0457] Add 20% piperidine / DMF 400ml to 50mmol of Ala loaded by the same method as in Example 4, stir for 10 minutes and then dehydrate. This process was repeated twice. Add DMF 450ml, stir for 10 minutes and then dehydrate. This process was repeated twice. Add MC 450ml, stir for 10 minutes and then dehydrate. This process was repeated three times. Add Fmoc-Leu-OH 35.34g, HOBt 13.52g, and DMF 900ml to another reactor, stir for 10 minutes to dissolve. After adding the solution to the Trityl-Ala reactor, add DIC 31.32ml, stir at room temperature for 4 hours and dehydrate. According to the amino acid configuration in Table 1, repeat a series of processes and perform the cleavage step (Example 9) to obtain 22.60g of crude solid. After 5g of the crude solid was purified by Prep LC, 1.27g of the final solid was obtained by freeze drying.
[0458] (97) Example 97
[0459] Add 20% piperidine / DMF 400ml to 50mmol of Ala loaded by the same method as in Example 4, stir for 10 minutes and then dehydrate. This process was repeated twice. Add DMF 450ml, stir for 10 minutes and then dehydrate. This process was repeated twice. Add MC 450ml, stir for 10 minutes and then dehydrate. This process was repeated three times. Add Fmoc-Leu-OH 35.34g, HOBt 13.52g, and DMF 900ml to another reactor, stir for 10 minutes to dissolve. After adding the solution to the Trityl-Ala reactor, add DIC 31.32ml, stir at room temperature for 4 hours and dehydrate. According to the amino acid configuration in Table 1, repeat a series of processes and perform the cleavage step (Example 9) to obtain 19.39g of crude solid. After 3g of the crude solid was purified by Prep LC, 1.08g of the final solid was obtained by freeze drying.
[0460] (98) Example 98
[0461] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Leu-OH (35.34g), 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.26g of crude solid. 3g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.46g of the final solid.
[0462] (99) Example 99
[0463] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.93g of Fmoc-Val-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 20.76g of crude solid. 3g of crude solid was purified by Prep LC, and then freeze-dried to obtain 1.13g of final solid.
[0464] (100) Embodiment 100
[0465] After adding 5 g of the crude solid obtained in Example 10, 240 mL of toluene was added. The reactor was heated to 110° C. and the reaction was carried out for 24 hours. After the reaction was completed, it was cooled to room temperature and the solid was dehydrated to obtain 4.4 g. The crude solid 4 g was purified by Prep LC and freeze-dried to obtain a final solid of 1.15 g.
[0466] (101) Embodiment 101
[0467] After adding 4 g of the crude solid obtained in Example 11, 192 mL of toluene was added. The reactor was heated to 110° C. and the reaction was carried out for 24 hours. After the reaction was completed, it was cooled to room temperature and the solid was dehydrated to obtain 3.7 g. After 3 g of the crude solid was purified by Prep LC, 0.86 g of the final solid was obtained by freeze drying.
[0468] (102) Embodiment 102
[0469] After adding 5 g of the crude solid obtained in Example 12, 240 mL of toluene was added. The reactor was heated to 110° C. and the reaction was carried out for 24 hours. After the reaction was completed, it was cooled to room temperature and the solid was dehydrated to obtain 3.9 g. After 3 g of the crude solid was purified by Prep LC, 1.15 g of the final solid was obtained by freeze drying.
[0470] (103) Example 103
[0471] After adding 4 g of the crude solid obtained in Example 15, 192 mL of toluene was added. The reactor was heated to 110° C. and the reaction was carried out for 24 hours. After the reaction was completed, it was cooled to room temperature and the solid was dehydrated to obtain 3.7 g. After 3.5 g of the crude solid was purified by Prep LC, 1.41 g of the final solid was obtained by freeze drying.
[0472] (104) Example 104
[0473] After adding 5 g of the crude solid obtained in Example 16, 240 mL of toluene was added. The reactor was heated to 110° C. and the reaction was carried out for 24 hours. After the reaction was completed, it was cooled to room temperature and the solid was dehydrated to obtain 4.9 g. After 4 g of the crude solid was purified by Prep LC, 2.14 g of the final solid was obtained by freeze drying.
[0474] (105) Embodiment 105
[0475] After adding 4 g of the crude solid obtained in Example 19, 192 mL of toluene was added. The reactor was heated to 110° C. and the reaction was carried out for 24 hours. After the reaction was completed, it was cooled to room temperature and the solid was dehydrated to obtain 3.7 g. After 3.5 g of the crude solid was purified by Prep LC, 1.49 g of the final solid was obtained by freeze drying.
[0476] (106) Example 106
[0477] Add 1 g of the crude solid obtained in Example 10 and 4 mL of isopropyl alcohol (IPA). 2 SO 40.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.95 g of crude solid. 0.5 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.14 g of final solid.
[0478] (107) Example 107
[0479] After adding 3 g of the crude solid obtained in Example 11, 12 mL of IPA was added. 2 SO 4 1.86mL, reflux stirring, HPLC confirmation of reaction completion. Cool to room temperature, dehydrate to obtain 2.1g of crude solid. 2g of crude solid was purified by Prep LC and freeze-dried to obtain 0.57g of final solid.
[0480] (108) Example 108
[0481] After adding 4 g of the crude solid obtained in Example 12, 16 mL of IPA was added. 2 SO 4 2.48mL, reflux stirring, and confirm the completion of the reaction by HPLC. Cool to room temperature and dehydrate to obtain 3.0g of crude solid. 2g of crude solid was purified by Prep LC and freeze-dried to obtain 0.62g of final solid.
[0482] (109) Example 109
[0483] After adding 1 g of the crude solid obtained in Example 100, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.72 g of crude solid. 0.5 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.11 g of final solid.
[0484] (110) Example 110
[0485] After adding 1 g of the crude solid obtained in Example 100, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.52 g of crude solid. 0.5 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.08 g of final solid.
[0486] (111) Example 111
[0487] After adding 1 g of the crude solid obtained in Example 101, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.59 g of crude solid. 0.5 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.14 g of final solid.
[0488] (112) Example 112
[0489] After adding 1 g of the crude solid obtained in Example 101, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.64 g of crude solid. 0.5 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.12 g of final solid.
[0490] (113) Example 113
[0491] After adding 1 g of the crude solid obtained in Example 102, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.39 g of crude solid. 0.3 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.07 g of final solid.
[0492] (114) Example 114
[0493] After adding 1 g of the crude solid obtained in Example 102, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.79 g of crude solid. 0.5 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.20 g of final solid.
[0494] (115) Example 115
[0495] After adding 1 g of the crude solid obtained in Example 10, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.48 g of crude solid. 0.3 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.08 g of final solid.
[0496] (116) Example 116
[0497] After adding 1 g of the crude solid obtained in Example 11, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.81 g of crude solid. 0.5 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.10 g of final solid.
[0498] (117) Example 117
[0499] After adding 1 g of the crude solid obtained in Example 12, 4 mL of IPA was added. 2 SO 4 0.62 mL, refluxed and stirred, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature and dehydrated to obtain 0.69 g of crude solid. 0.5 g of crude solid was purified by Prep LC and freeze-dried to obtain 0.11 g of final solid.
[0500] (118) Example 118
[0501] After adding 1 g of the crude solid obtained in Example 30, 4 mL of IPA was added. 2 SO 4 (0.62 mL), refluxed with stirring, and the reaction was confirmed to be complete by HPLC. Cooled to room temperature, dehydrated, and a crude solid of 0.48 g was obtained. The crude solid of 0.4 g was purified by PrepLC and freeze-dried to obtain a final solid of 0.27 g.
[0502] (119) Example 119
[0503] 20% piperidine / DMF 400ml was added to 50mmol of Val loaded by the same method as in Example 8, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 31.13g of Fmoc-Ala-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Val reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 11.94g of crude solid. 3g of the crude solid was purified by Prep LC, and then freeze-dried to obtain 1.07g of the final solid.
[0504] (120) Example 120
[0505] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 31.13g of Fmoc-Ala-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 13.57g of crude solid. 3g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.44g of the final solid.
[0506] (121) Example 121
[0507] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 31.13g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 12.91g of crude solid. 3g of the crude solid was purified by Prep LC, and 0.89g of the final solid was obtained by freeze drying.
[0508] (122) Example 122
[0509] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. Fmoc-Gly-OH (29.73g), 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 11.82g of crude solid. 3g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.26g of the final solid.
[0510] (123) Example 123
[0511] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 31.13g of Fmoc-Leu-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 12.44g of crude solid. 3g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.08g of the final solid.
[0512] (124) Example 124
[0513] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 33.93g of Fmoc-Val-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 10.47g of crude solid. 3g of the crude solid was purified by Prep LC and freeze-dried to obtain 1.20g of the final solid.
[0514] (125) Example 125
[0515] 20% piperidine / DMF 400ml was added to 50mmol of Leu loaded by the same method as in Example 5, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of DMF was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated twice. 450ml of MC was added, and the mixture was dehydrated after stirring for 10 minutes. This process was repeated three times. 41.15g of Fmoc-D Asp(OtBu)-OH, 13.52g of HOBt, and 900ml of DMF were added to another reactor, and the mixture was dissolved after stirring for 10 minutes. After the solution was added to the Trityl-Leu reactor, 31.32ml of DIC was added, and the mixture was stirred at room temperature for 4 hours and dehydrated. According to the amino acid configuration in Table 1, a series of processes were repeated and the cleavage step (Example 9) was performed to obtain 8.41g of crude solid. 4g of crude solid was purified by Prep LC, and 2.06g of final solid was obtained by freeze drying.
[0516] Experimental Example 1: Evaluation of dissolution stability
[0517] The peptides of Examples 10 to 125 were dissolved at a concentration of 1 mg / 1 ml and stored at 40° C. and RH 75% for 7 days to confirm changes in content. The results are shown in Table 2 below.
[0518] Table 2
[0519]
[0520]
[0521]
[0522]
[0523] As can be seen from Table 2 above, in most of the embodiments, the content was maintained at more than 50% after 7 days, and the stability was very excellent.
[0524] Experimental Example 2: Evaluation of anti-inflammatory effects using mouse macrophages (in vitro)
[0525] The anti-inflammatory effect was evaluated for the typical examples in the above examples. Specifically, the typical examples with 5 amino acid residues are Examples 10, 32, 41, 55, 59 and 91, the typical examples with 6 amino acid residues are Examples 11 and 30, the typical example with 7 amino acid residues is Example 86, and the typical example with 8 amino acid residues is Examples 103 and 104. In order to confirm whether these examples have anti-inflammatory effects, Raw 264.7 cells as a macrophage cell line were used to confirm the changes in the secretion of inflammatory cytokines by enzyme-linked immunosorbent assay (ELISA).
[0526] Specifically, for Raw264.7 cells (Korean Cell Line Bank, 40071), the pretreatment of the embodiment was diluted with 10nM, 100nM, 1μM, and 10μM concentrations for 1 hour, and then LPS (Sigma, L6529) at a concentration of 1μg / ml was added to induce an inflammatory response. After 24 hours of induction, the cell culture supernatant was recovered and analyzed. Enzyme-linked immunosorbent assay was performed using Mouse IL-6 Quantikine ELISA Kit (R&D systems, M6000B), TNF-alpha Quantikine ELISA Kit (R&D systems, MTA00B) and Mouse IL-1beta / IL-1F2 Quantikine ELISA Kit (R&D systems, MLB00C) according to the manufacturer's manual.
[0527] Results, refer to Figure 1a , 5mer in Example 10 significantly reduced the IL-1β level increased by LPS at 100 nM and 1 μM concentrations, referring to Figure 1c , significantly reduced the TNFα level increased by LPS at concentrations of 10 nM and 1 μM.
[0528] Reference Figure 2a In Example 32, the 5mer significantly reduced the IL-1β level increased by LPS at concentrations of 10 nM, 100 nM and 1 μM.
[0529] Reference Figure 3a In Example 41, the 5mer significantly reduced the IL-1β level and IL-6 level increased by LPS at the concentrations of 100 nM and 1 μM, respectively.
[0530] Reference Figure 4a and Figure 5a , Examples 55 and 59 of the 5mers significantly reduced the IL-1β level increased by LPS at a concentration of 100 nM.
[0531] Reference Figure 6a and 6b In Example 91, the 5mer reduced the IL-1β level increased by LPS at all concentrations (10 nM, 100 nM, 1 μM, 10 μM), and only significantly reduced the IL-6 level increased by LPS at a concentration of 1 μM.
[0532] Reference Figure 7b In Example 30, the 6mer significantly reduced the IL-6 level increased by LPS at a concentration of 10 nM.
[0533] Reference Figure 8c , the 6mer in Example 11 significantly reduced the TNFα level increased by LPS at a concentration of 10 μM.
[0534] Reference Figure 9a In Example 86, the 7mer significantly reduced the IL-1β level increased by LPS at concentrations of 10 nM, 1 μM, and 10 μM.
[0535] Reference Fig.10a , Example 103 of 8mer significantly reduced the IL-1β level increased by LPS at a concentration of 1 μM,
[0536] Reference Fig.11c , Example 104 of the 8mer significantly reduced the TNFα level increased by LPS at a concentration of 10 nM.
[0537] That is, in typical embodiments of the present invention, namely, in Examples 10, 32, 41, 55, 59, 86, 91 and 103, a significant anti-inflammatory effect is exhibited by regulating the secretion of IL-1β secreted from immune cells, in Examples 30, 32, 41 and 91, a significant anti-inflammatory activity is exhibited by regulating the secretion of IL-6, and in Examples 10, 11, 59 and 104, a significant anti-inflammatory activity is exhibited by regulating the secretion of TNFα.
[0538] The features, structures, effects, etc. described in the embodiments described above are included in at least one embodiment of the present invention, and are not necessarily limited to one embodiment. In addition, the features, structures, effects, etc. shown in each embodiment can be combined or modified by a person skilled in the art to which the embodiments belong for other embodiments. Therefore, the contents related to these combinations and modifications should be interpreted as being included within the scope of the present invention.
[0539] Furthermore, although the present invention is described above with the embodiment as the center, these are only examples rather than limiting the present invention, and those skilled in the art to which the present invention belongs will understand that various modifications and applications not illustrated above are possible without departing from the essential features of the present embodiment. For example, the various components specifically shown in the embodiment can be implemented by modification. And the differences related to these modifications and applications should be understood to be included in the scope of the present invention as defined by the attached invention claims. Sequence Listing <110> EYEBIO KOREA <120> Novel peptide compound or pharmaceutically acceptable salt thereof <130> EYEB20P-0001-KR-PRI <150> KR 10-2019-0059628 <151> 2019-05-21 <160> 116 <170> KoPatentIn 3.0 <210> 1 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Example 10 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 1 Xaa Gly Gln Asp Gly 1 5 <210> 2 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 11 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 2 Xaa Gly Gln Asp Gly Leu 1 5 <210> 3 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Example 12 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 3 Xaa Gly Gln Asp Gly Leu Ala 1 5 <210> 4 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 13 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 4 Xaa Gly Gln Ala Gly 1 5 <210> 5 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 14 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 5 Xaa Gly Gln Ala Gly Leu Ala 1 5 <210> 6 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Embodiment 15 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 6 Xaa Gly Gln Asp Gly Leu Ala Gly 1 5 <210> 7 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Example 16 <400> 7 Gln Asp Gly Leu Ala Gly Pro Lys 1 5 <210> 8 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Embodiment 17 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 8 Xaa Gly Gln Leu Gly Leu Ala Gly 1 5 <210> 9 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Embodiment 18 <400> 9 Gln Leu Gly Leu Ala Gly Pro Lys 1 5 <210> 10 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 19 <400> 10 Asp Gly Leu Ala Gly Pro Lys 1 5 <210> 11 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 20 <400> 11 Leu Gly Leu Ala Gly Pro Lys 1 5 <210> 12 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 21 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 12 Xaa Gly Gln Asp Val 1 5 <210> 13 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (1) <223> X at position 1 is trans-4-hydroxy-L-proline <400> 13 Xaa Gly Gln Asp Val Leu 1 5 <210> 14 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 23 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 14 Xaa Gly Gln Asp Val Leu Ala 1 5 <210> 15 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Embodiment 24 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 15 Xaa Gly Gln Asp Val Leu Ala Gly 1 5 <210> 16 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 25 <400> 16 Leu Ala Gly Pro Lys 1 5 <210> 17 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 26 <400> 17 Gly Leu Ala Gly Pro Lys 1 5 <210> 18 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 27 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 18 Xaa Gly Leu Ala Gly Pro Lys 1 5 <210> 19 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 28 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 19 Xaa Gly Gln Asp Gly Pro Lys 1 5 <210> 20 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 29 <400> 20 Gly Gln Asp Gly Leu Ala 1 5 <210> twenty one <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 30 <400> twenty one Gln Asp Gly Leu Ala Gly 1 5 <210> twenty two <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 31 <400> twenty two Asp Gly Leu Ala Gly Pro 1 5 <210> twenty three <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 32 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> twenty three Xaa Gly Gln Asp Leu 1 5 <210> twenty four <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 33 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> twenty four Xaa Gly Gln Asp Ala 1 5 <210> 25 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 34 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 25 Xaa Gly Gln Asp Val Leu 1 5 <210> 26 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 35 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 26 Xaa Gly Gln Asp Leu Leu 1 5 <210> 27 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 36 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 27 Xaa Gly Gln Asp Ala Leu 1 5 <210> 28 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 37 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 28 Xaa Gly Gln Asp Val Leu Ala 1 5 <210> 29 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 38 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 29 Xaa Gly Gln Asp Leu Leu Ala 1 5 <210> 30 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 39 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 30 Xaa Gly Gln Asp Ala Leu Ala 1 5 <210> 31 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 40 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is trans-4-hydroxy-D-proline <400> 31 Xaa Gly Gln Asp Gly 1 5 <210> 32 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 41 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is cis-4-fluoro-L-proline <400> 32 Xaa Gly Gln Asp Gly 1 5 <210> 33 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 42 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is trans-4-amino-L-proline <400> 33 Xaa Gly Gln Asp Gly 1 5 <210> 34 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 43 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4-difluoro-L-proline <400> 34 Xaa Gly Gln Asp Gly 1 5 <210> 35 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 44 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4-methylene-L-proline <400> 35 Xaa Gly Gln Asp Gly 1 5 <210> 36 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 45 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is trans-4-hydroxy-D-proline <400> 36 Xaa Gly Gln Asp Gly Leu 1 5 <210> 37 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 46 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is cis-4-fluoro-L-proline <400> 37 Xaa Gly Gln Asp Gly Leu 1 5 <210> 38 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 47 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is trans-4-amino-L-proline <400> 38 Xaa Gly Gln Asp Gly Leu 1 5 <210> 39 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 48 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4-difluoro-L-proline <400> 39 Xaa Gly Gln Asp Gly Leu 1 5 <210> 40 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 49 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4-methylene-L-proline <400> 40 Xaa Gly Gln Asp Gly Leu 1 5 <210> 41 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 50 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is trans-4-hydroxy-D-proline <400> 41 Xaa Gly Gln Asp Gly Leu Ala 1 5 <210> 42 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 51 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is cis-4-fluoro-L-proline <400> 42 Xaa Gly Gln Asp Gly Leu Ala 1 5 <210> 43 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 52 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is trans-4-amino-L-proline <400> 43 Xaa Gly Gln Asp Gly Leu Ala 1 5 <210> 44 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 53 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4-difluoro-L-proline <400> 44 Xaa Gly Gln Asp Gly Leu Ala 1 5 <210> 45 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 54 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4-methylene-L-proline <400> 45 Xaa Gly Gln Asp Gly Leu Ala 1 5 <210> 46 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 55 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4,4-dimethyl-L-proline <400> 46 Xaa Gly Gln Asp Gly 1 5 <210> 47 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 56 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4,4-dimethyl-L-proline <400> 47 Xaa Gly Gln Asp Gly Leu 1 5 <210> 48 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 57 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is 4,4-dimethyl-L-proline <400> 48 Xaa Gly Gln Asp Gly Leu Ala 1 5 <210> 49 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 58 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (3) <223> Xaa at position 3 is D-glutamine <400> 49 Xaa Gly Xaa Asp Gly 1 5 <210> 50 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 59 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is D-aspartic acid <400> 50 Xaa Gly Gln Xaa Gly 1 5 <210> 51 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 60 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (3) <223> Xaa at position 3 is D-glutamine <400> 51 Xaa Gly Xaa Asp Gly Leu 1 5 <210> 52 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 61 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is D-aspartic acid <400> 52 Xaa Gly Gln Xaa Gly Leu 1 5 <210> 53 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 62 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is D-leucine <400> 53 Xaa Gly Gln Asp Gly Xaa 1 5 <210> 54 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 63 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (3) <223> Xaa at position 3 is D-glutamine <400> 54 Xaa Gly Xaa Asp Gly Leu Ala 1 5 <210> 55 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 64 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is D-aspartic acid <400> 55 Xaa Gly Gln Xaa Gly Leu Ala 1 5 <210> 56 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 65 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is D-leucine <400> 56 Xaa Gly Gln Asp Gly Xaa Ala 1 5 <210> 57 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 66 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (7) <223> Xaa at position 7 is D-alanine <400> 57 Xaa Gly Gln Asp Gly Leu Xaa 1 5 <210> 58 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 67 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 58 Xaa Gly Gln Glu Gly 1 5 <210> 59 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 68 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 59 Xaa Gly Gln Glu Gly Leu 1 5 <210> 60 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 69 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 60 Xaa Gly Gln Glu Gly Leu Ala 1 5 <210> 61 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 70 <400> 61 Gln Glu Gly Leu Ala Gly 1 5 <210> 62 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 71 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 62 Xaa Gly Gln Asp Gly Val 1 5 <210> 63 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 72 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 63 Xaa Gly Gln Asp Gly Val Ala 1 5 <210> 64 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 73 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 64 Xaa Ala Gln Asp Gly 1 5 <210> 65 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 74 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 65 Xaa Val Gln Asp Gly 1 5 <210> 66 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 75 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 66 Xaa Leu Gln Asp Gly 1 5 <210> 67 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 76 <400> 67 Pro Gly Gln Asp Gly 1 5 <210> 68 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 77 <400> 68 Pro Gly Gln Asp Gly Leu 1 5 <210> 69 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 78 <400> 69 Pro Gly Gln Asp Gly Leu Ala 1 5 <210> 70 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 79 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 70 Xaa Gly Gln Asn Gly Leu Ala 1 5 <210> 71 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 80 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 71 Xaa Gly Gln His Gly Leu Ala 1 5 <210> 72 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 81 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 72 Xaa Gly Gln Asn Gly Leu 1 5 <210> 73 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 82 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 73 Xaa Gly Gln His Gly Leu 1 5 <210> 74 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 83 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (5) <223> Xaa at position 5 is 2-aminoisobutyric acid <400> 74 Xaa Gly Gln Asp Xaa Leu Ala 1 5 <210> 75 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 84 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is 2-aminoisobutyric acid <400> 75 Xaa Gly Gln Xaa Gly Leu 1 5 <210> 76 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 85 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (5) <223> Xaa at position 5 is 2-aminoisobutyric acid <400> 76 Xaa Gly Gln Asp Xaa 1 5 <210> 77 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 86 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 77 Xaa Gly Gln Glu Leu Leu Ala 1 5 <210> 78 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 87 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 78 Xaa Gly Gln Glu Val Leu Ala 1 5 <210> 79 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 88 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 79 Xaa Gly Gln Glu Leu Leu 1 5 <210> 80 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 89 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 80 Xaa Gly Gln Glu Val Leu 1 5 <210> 81 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 90 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 81 Xaa Gly Gln Glu Leu 1 5 <210> 82 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 91 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 82 Xaa Gly Gln Glu Val 1 5 <210> 83 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 92 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (5) <223> Xaa at position 5 is 2-aminoisobutyric acid <400> 83 Xaa Gly Gln Glu Xaa Leu Ala 1 5 <210> 84 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 93 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (5) <223> Xaa at position 5 is La-tert-butylglycine <400> 84 Xaa Gly Gln Glu Xaa Leu Ala 1 5 <210> 85 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 94 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (5) <223> Xaa at position 5 is phenylglycine <400> 85 Xaa Gly Gln Glu Xaa Leu Ala 1 5 <210> 86 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 95 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 86 Xaa Gly Gln Leu Val 1 5 <210> 87 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 96 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 87 Xaa Gly Gln Leu Leu Leu Ala 1 5 <210> 88 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 97 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 88 Xaa Gly Gln Leu Val Leu Ala 1 5 <210> 89 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 98 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 89 Xaa Gly Gln Leu Leu Leu 1 5 <210> 90 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 99 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 90 Xaa Gly Gln Leu Val Leu 1 5 <210> 91 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 100 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is apartimide or aminosuccinimide <400> 91 Xaa Gly Gln Xaa Gly 1 5 <210> 92 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 101 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is apartimide or aminosuccinimide <400> 92 Xaa Gly Gln Xaa Gly Leu 1 5 <210> 93 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 102 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is apartimide or aminosuccinimide <400> 93 Xaa Gly Gln Xaa Gly Leu Ala 1 5 <210> 94 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Embodiment 103 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is apartimide or aminosuccinimide <400> 94 Xaa Gly Gln Xaa Gly Leu Ala Gly 1 5 <210> 95 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Embodiment 104 <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is apartimide or aminosuccinimide <400> 95 Gln Xaa Gly Leu Ala Gly Pro Lys 1 5 <210> 96 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 105 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is apartimide or aminosuccinimide <400> 96 Xaa Gly Leu Ala Gly Pro Lys 1 5 <210> 97 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 106 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (5) <223> Xaa at position 5 is glycine substituted with isopropyl ester <400> 97 Xaa Gly Gln Asp Xaa 1 5 <210> 98 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 107 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is leucine substituted with isopropyl ester <400> 98 Xaa Gly Gln Asp Gly Xaa 1 5 <210> 99 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 108 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (7) <223> Xaa at position 7 is alanine substituted with isopropyl ester <400> 99 Xaa Gly Gln Asp Gly Leu Xaa 1 5 <210> 100 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 109 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is apartimide or aminosuccinimide <220> <221> MISC_FEATURE <222> (5) <223> Xaa at position 5 is glycine substituted with isopropyl ester <400> 100 Xaa Gly Gln Xaa Xaa 1 5 <210> 101 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 110 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is aspartic acid substituted with isopropyl ester <220> <221> MISC_FEATURE <222> (5) <223> Xaa at position 5 is glycine substituted with isopropyl ester <400> 101 Xaa Gly Gln Xaa Xaa 1 5 <210> 102 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 111 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is apartimide or aminosuccinimide <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is leucine substituted with isopropyl ester <400> 102 Xaa Gly Gln Xaa Gly Xaa 1 5 <210> 103 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 112 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is aspartic acid substituted with isopropyl ester <220> <221> MISC_FEATURE <222> (6) <223> Xaa at position 6 is leucine substituted with isopropyl ester <400> 103 Xaa Gly Gln Xaa Gly Xaa 1 5 <210> 104 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 113 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is apartimide or aminosuccinimide <220> <221> MISC_FEATURE <222> (7) <223> Xaa at position 7 is alanine substituted with isopropyl ester <400> 104 Xaa Gly Gln Xaa Gly Leu Xaa 1 5 <210> 105 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 114 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is aspartic acid substituted with isopropyl ester <220> <221> MISC_FEATURE <222> (7) <223> Xaa at position 7 is alanine substituted with isopropyl ester <400> 105 Xaa Gly Gln Xaa Gly Leu Xaa 1 5 <210> 106 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 115 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is aspartic acid substituted with isopropyl ester <400> 106 Xaa Gly Gln Xaa Gly 1 5 <210> 107 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 116 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is aspartic acid substituted with isopropyl ester <400> 107 Xaa Gly Gln Xaa Gly Leu 1 5 <210> 108 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Embodiment 117 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is aspartic acid substituted with isopropyl ester <400> 108 Xaa Gly Gln Xaa Gly Leu Ala 1 5 <210> 109 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 118 <220> <221> MISC_FEATURE <222> (2) <223> Xaa at position 2 is apartimide or aminosuccinimide <400> 109 Gln Xaa Gly Leu Ala Gly 1 5 <210> 110 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 119 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 110 Xaa Gly Gln Ala Val 1 5 <210> 111 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 120 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 111 Xaa Gly Gln Ala Leu 1 5 <210> 112 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 121 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 112 Xaa Gly Gln Leu Leu 1 5 <210> 113 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 122 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 113 Xaa Gly Gln Ala Gly Leu 1 5 <210> 114 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 123 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 114 Xaa Gly Gln Ala Leu Leu 1 5 <210> 115 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Embodiment 124 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <400> 115 Xaa Gly Gln Ala Val Leu 1 5 <210> 116 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Embodiment 125 <220> <221> MISC_FEATURE <222> (1) <223> Xaa at position 1 is (2S,4R) trans-4-hydroxy-L-proline <220> <221> MISC_FEATURE <222> (4) <223> Xaa at position 4 is D-aspartic acid <400> 116 Xaa Gly Gln Xaa Leu 1 5
Claims
1. A novel peptide compound selected from the following amino acid sequences or a pharmaceutically acceptable salt thereof: Hyp-Gly-Gln-Glu-Leu-Leu-Ala, Hyp-Gly-Gln-Glu-Val-Leu-Ala, or Hyp-Gly-Gln-Glu-Aib-Leu-Ala.
2. A novel peptide compound having an amino acid sequence of Hyp-Gly-Gln-Glu-Aib-Leu-Ala or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition for preventing or treating inflammation, comprising the peptide according to claim 1 or 2 as an active ingredient.
4. A cosmetic composition having an anti-inflammatory effect, comprising the peptide according to claim 1 or 2 as an active ingredient.
Citation Information
Patent Citations
Fermented balloon flower using detoxicating, fermenting and steaming process and manufacturing method thereof
KR1020190059628A
Compounds which inhibit neuronal exocytosis (II)
CN104321048A
Novel cyclic peptides and uses thereof
CN109563134A
